Search results
Results from the WOW.Com Content Network
For premium support please call: 800-290-4726 more ways to reach us
In addition to CRISPR research, the IGI works to advance public understanding of CRISPR and genome engineering and guide the ethical use of these technologies. Free public resources include: CRISPRpedia — a free textbook-style resource for learning about the biology, applications, and ethics of CRISPR and genome editing, with chapters edited ...
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.
Off-target genome editing refers to nonspecific and unintended genetic modifications that can arise through the use of engineered nuclease technologies such as: clustered, regularly interspaced, short palindromic repeats ()-Cas9, transcription activator-like effector nucleases (), meganucleases, and zinc finger nucleases (ZFN). [1]
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $50.84, marking a -0.88% move from the previous day.
Geothermal power is considered to be a sustainable, renewable source of energy because the heat extraction is small compared with the Earth's heat content. [7] The greenhouse gas emissions of geothermal electric stations average 45 grams of carbon dioxide per kilowatt-hour of electricity, or less than 5% of those of conventional coal-fired plants.
Mark Z. Jacobson, professor of civil and environmental engineering at Stanford University and director of its Atmosphere and Energy Program says producing all new energy with wind power, solar power, and hydropower by 2030 is feasible and existing energy supply arrangements could be replaced by 2050. Barriers to implementing the renewable ...
Nevertheless, there remains a few limitations of the technology's use in gene therapy: the relatively high frequency of off-target effect, the requirement for a PAM sequence near the target site, p53 mediated apoptosis by CRISPR-induced double-strand breaks and immunogenic toxicity due to the delivery system typically by virus.